Executive Management

Jeppe Ragnar Andersen

Jeppe is the CEO of NBCD, as well as the Group CEO of Sanos Group (the parent company of NBCD, Sanos Clinic, Sanos Supply and Studies&Me).

Jeppe holds a master’s in Pharmaceutical Science (M.Sc. Pharm) from University of Copenhagen, Denmark, and joined Nordic Bioscience in 2007 as a CRA. In 2010 he became Head of Clinical Development in 2010, and in 2014 he transitioned into his position as the CEO of NBCD.

Jeppe has been involved on an operational and executive level in numerous clinical studies with more than 15,000 patients within various therapeutic fields but primarily within osteoporosis and osteoarthritis leading to market approved drugs in both indications. Jeppe has been leading the company from 3 employees to more than 100.

With his history of success in building and growing organizations, his strong expertise from both CRO and Investigator perspective, and his in-depth project leadership in clinical development, he has an ability to identify market trends and conceptualize strategies with an aim of innovation to improve work and business processes.

Asger Reinstrup Bihlet

Asger is the Chief Scientific Officer of Sanos Group and is an internationally renowned expert in osteoarthritis (OA) drug development, OA pain, and clinical trial design. He joined NBCD in 2013,  assumed the position as Medical Director in 2014 and in 2021, he transitioned into his current position.

Asger holds a master’s in Pharmaceutical Science (M.Sc. Pharm) from University of Copenhagen, Denmark, and a PhD from University of Southern Denmark on osteoarthritis clinical trial design. He has held several leading positions in pharma and clinical research organizations within regulatory affairs, medical affairs, and clinical science, and has published more than 30 peer-reviewed papers, primarily on OA science, in high-ranking journals, and has been cited more than 1000 times. Asger has played key roles in the design and conduct of landmark osteoarthritis trials, including the sprifermin FORWARD trial published in JAMA in 2019, and is a frequent speaker at OARSI, EULAR, and ACR conferences, where more than 50 original abstracts have been presented, in addition to invited speaker sessions on OA trial design and placebo response mitigation.

As Chief Scientific Officer, Asger currently leads the scientific affairs activities of Sanos Group and the subsidiary of NBCD, a Contract-Research Organization specialized in OA clinical trials. As chief scientist, Asger was the primary responsible person for the design and conduct of 3 global phase III, 15 phase II and 5 phase I trials totaling approximately 10,000 study participants evaluating experimental treatments primarily within knee osteoarthritis.

Asger is actively researching in the fields of osteoarthritis with a particular focus on optimizing clinical trial methodology and outcome.

Casper Clemmensen

Casper is the Chief Commercial Officer of Sanos Group and is responsible for business development as well as the marketing efforts across the four business units.

Casper holds a master’s in Pharmaceutical Science (M.Sc. Pharm) from University of Copenhagen, Denmark, and joined NBCD in 2016 as Clinical Trial Leader. In 2019, he transitioned into the position as Business Development Director and in 2022 he was appointed Chief Commercial Officer of Sanos Group.  

Casper has a longstanding background (20 years) working with clinical operations and strategic business development in various pharma, biotech and CRO companies. Over the years, Casper has gained unique insight to the different actors of the life-science industry, which has led to a profound understanding of current and future Sanos partners resulting in strong strategic and scientific alliances. 

Casper has dedicated most of his professional career to the fields of dermatology and rheumatology – the latter through a deep specialization within osteoarthritis.

Jakob Brix Christensen

Jakob is the Chief Financial Officer of Sanos Group, and has been with the company since the beginning of 2024. 

Jakob holds a master’s of Business Administration and Economics (cand. merc.) from Aarhus University, Denmark, and is a seasoned financial executive with over 15 years of experience in international biotech and life science companies. With a proven track record as a CFO in both Denmark and the USA, Jakob brings a wealth of expertise in financial management, business development, and investor relations.

Driven by a passion for healthcare, Jakob is dedicated, results-oriented, and possesses excellent communication skills. Jakob's proactive approach and adeptness in managing stakeholders at all levels make him an invaluable asset to the Sanos team.

Christoffer von Sehested

Christoffer is the Chief Innovation Officer of Sanos Group and has been with the company since 2020. He holds a master’s in Pharmaceutical Science (M.Sc. Pharm) from University of Copenhagen, Denmark, and has been certified as Project Management Professional by the Project Management Institute. Christoffer started his career as a Clinical Research Associate in 2012.

Before joining NBCD, Christoffer has held various positions within clinical operations and data management in both pharma, biotech and CRO; thereby gaining experience from phase 1 to 4 including numerous inspections from FDA and EMA.

Christoffer’s main focus is seeing the bigger picture and implementing solutions that enhances the performance across all involved team members from synopsis to final study report.

Mickey Clausen

Mickey is the Chief Information Officer at Sanos Group and has been with the company since Februar 2021. He holds multiple certifications including GIAC Information Security Professional (GISP from SANS Institute), Pentest+, CySA+, Security+ (CompTIA), VCPD55-DCV (VMware Certified Professional) and ITIL Foundation.

Mickey joined Sanos Group as an IT-Consultant to assist with the IT-carveout during a demerger from our parent branch Nordic Bioscience. Later on, he accepted the position as CIO and thus relocating from Dubai, where he resided and worked for almost 7 years. He has more than 19 years of IT experience and has worked in various industries such as fitness/welness, various government entities, and CRO's like NBCD.

As CIO, Mickey is responsible for the Cyber Security program, IT infrastructure, and ensuring the Governance and compliance for the entire Sanos Group.

Gunnleyg Reeckmann

Gunnleyg is the HR Director of Sanos Group and joined the company in 2022. She holds a master's in Strategy and Management from Aarhus School of Business, Denmark. 

Previously, Gunnleyg has worked both strategically and operationally with HR in the financial industry for the last 15 years. She is specialized in leadership development, building processes and talent recruitment.

Kirsten Annette Nielsen

Kirsten is the QA Director at Sanos Group and has been with the company since January 2023. She holds a PhD in Biotechnology from University of Aarhus and has 25+ peer reviewed papers in high-ranking journals on research performed as postdoctoral fellow, assistant and associate professor at Danish Universities and Research Laboratories.

Kirsten commenced as Lead Auditor with certificate from Dansk Standard in 2005 on ISO 9001:2000 and acted as QA associate at Danish Epilepsy Centre 2004-2008. She has managed Research and Laboratory Facilities with Gene tests on human CYP P450 enzymes responsible for metabolism of drugs. From 2008 QA obligations, management and audits have covered certifications and accreditations according to ISO 17025, ISO 13485, GMP, GDP, GCP and Pharmacovigilance.

Kirstens responsibility is to ensure overarching QA principles across the Sanos Group and adjust individual goals for the independent business within GxP regulated areas.